Compare SCWO & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCWO | CING |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | 27 | 13 |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.2M | 74.9M |
| IPO Year | N/A | N/A |
| Metric | SCWO | CING |
|---|---|---|
| Price | $2.51 | $8.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $37.00 |
| AVG Volume (30 Days) | 42.0K | ★ 303.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5,945.19 | N/A |
| Revenue Next Year | $106.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $3.20 |
| 52 Week High | $3.55 | $7.92 |
| Indicator | SCWO | CING |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 72.08 |
| Support Level | $2.33 | $3.58 |
| Resistance Level | $3.10 | N/A |
| Average True Range (ATR) | 0.21 | 0.48 |
| MACD | -0.05 | 0.15 |
| Stochastic Oscillator | 18.87 | 95.36 |
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.